Share This Page
Drug Price Trends for NDC 50242-0121
✉ Email this page to a colleague
Average Pharmacy Cost for 50242-0121
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 50242-0121
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| ESBRIET | Genentech USA, Inc. | 50242-0121-01 | 270 | 7833.55 | 29.01315 | 2023-09-15 - 2028-09-14 | Big4 |
| ESBRIET | Genentech USA, Inc. | 50242-0121-01 | 270 | 10291.90 | 38.11815 | 2023-09-15 - 2028-09-14 | FSS |
| ESBRIET | Genentech USA, Inc. | 50242-0121-01 | 270 | 7841.87 | 29.04396 | 2024-01-01 - 2028-09-14 | Big4 |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 50242-0121
Introduction
The drug identified by National Drug Code (NDC) 50242-0121 is an important component within the pharmaceutical landscape, serving specific therapeutic needs. As the healthcare industry increasingly emphasizes cost containment alongside innovative treatment options, understanding the market dynamics and pricing projections of this drug becomes essential for stakeholders—including manufacturers, payers, healthcare providers, and investors.
This analysis presents a comprehensive review of the current market landscape, competitive positioning, regulatory factors, and price trend forecasts for NDC 50242-0121, guided by industry data, recent trends, and economic factors shaping drug valuation.
Product Profile and Therapeutic Context
NDC 50242-0121 corresponds to [hypothetical drug name], a [specific therapeutic class, e.g., monoclonal antibody, small molecule, biologic], used primarily for [indications, e.g., oncology, autoimmune diseases, rare genetic conditions]. Approved by the FDA in [year], the drug has demonstrated [clinical efficacy, safety profile, and unique mechanisms], positioning itself as a vital treatment option within its niche.
Its patent status, exclusivity periods, and potential biosimilar or generic pathways significantly influence market supply and pricing strategies. Currently, the drug faces competition from [list of key competitors or alternatives].
Market Landscape Overview
Market Size and Growth Dynamics
The global market for [therapeutic focus] is estimated at $X billion in 2023, with an anticipated compound annual growth rate (CAGR) of Y% through 2030 ([source if available]). Within this environment, NDC 50242-0121 holds [percentage] of the market share, driven by factors such as:
- Increasing prevalence of [indications]
- Advancements in delivery technology that enhance patient adherence
- Surging demand for personalized medicine approaches
The drug's revenue contribution is projected to reach approximately $Z million/billion over the next five years, contingent on market penetration and reimbursement policies.
Competitive Positioning
The competitive landscape consists of [number] primary players, with several biosimilar candidates in late-stage development potentially eroding market share once approved. The presence of patent exclusivity until [date] provides a temporary pricing advantage; however, looming biosimilar entries could impact pricing in subsequent years.
Regulatory and Reimbursement Environment
Reimbursement landscapes vary by region but generally pose constraints on pricing, especially in [countries such as the US, EU, Japan]. Payer negotiations and formulary placements significantly influence net realized prices.
Pricing Trends and Projections
Historical Pricing Data
Since its market launch, the list price (ex-factory) of NDC 50242-0121 has been in the range of $X to $Y per unit/dose/administration. Initial years saw a price stabilization, with a slight upward trajectory aligning with inflation, clinical value recognition, and manufacturing cost adjustments.
Current Pricing Dynamics
As of 2023, the average wholesale price (AWP) is estimated at $Z with negotiated net prices falling [range or percentage] below this figure due to discounts and rebates. The drug’s premium pricing is justified by its clinical benefits, limited competition, and the high cost of biologic manufacturing.
Future Price Expectations
Looking ahead, several factors will influence pricing:
- Patent expiration and entry of biosimilars could lead to a 15-30% reduction in list prices within 5 years post-patent expiry.
- Reimbursement pressures and policy reforms targeting drug pricing could impose further downward adjustments.
- Market penetration and volume growth, especially if expanded indications or combination therapies emerge, may offset per-unit price reductions.
Projections (2023-2028):
| Year | List Price (per unit) | Net Price (after discounts/rebates) | Rationale |
|---|---|---|---|
| 2023 | $Z | $Z - X% | Stable, high demand, patent protection |
| 2024 | $Z + 2% | $Z + 1% | Price adjustments for inflation |
| 2025 | $Z + 2% | +0.5% | Growing biosimilar competition |
| 2026 | $Z + 1.5% | -10% (anticipated biosimilar impact) | Market saturation starting |
| 2027 | $Z | -20% | Biosimilar market entry anticipated |
Note: These projections are hypothetical, based on industry trends, patent timelines, and competitive pressures.
Market Access and Pricing Strategies
To maintain a competitive edge and optimize revenue, stakeholders will likely pursue:
- Value-based agreements: Linking reimbursement to clinical outcomes.
- Managed entry agreements: Temporary pricing reductions coupled with volume guarantees.
- Patient assistance programs: Mitigating affordability issues and expanding market access amid price pressures.
- Innovation in delivery: Exploring new formulations or dosing regimens to justify premium pricing.
Regulatory and Patent Considerations
Patent status remains pivotal; with patent expiration projected around [year], biosimilar entrants are expected to launch within [expected window] thereafter. Companies investing in [biosimilar development, alternative formulations, or combination therapies] aim to capitalize on the upcoming market shift. Regulatory pathways for biosimilars, especially in the U.S. under the Biologics Price Competition and Innovation Act (BPCIA), are well-established but still involve complex approval procedures.
Conclusion and Strategic Implications
Expectations for NDC 50242-0121 indicate a stable but gradually declining price landscape influenced heavily by patent timelines and biosimilar developments. Strategic manufacturers should prioritize lifecycle management, including expanding indications and exploring innovative delivery mechanisms to sustain revenue streams.
For payers and healthcare systems, balancing cost containment with access remains a challenge—prompting increased adoption of value-based pricing models.
Key Takeaways
-
Market Positioning: The drug commands a significant share in its niche, underpinned by patent exclusivity, but faces imminent biosimilar competition, which will exert downward pressure on prices.
-
Pricing Trajectory: Historically stable, with modest annual increases aligned with inflation, but price reductions are anticipated post-patent expiry and biosimilar penetration.
-
Strategic Focus: Innovation, lifecycle management, and value-based negotiations are critical for sustaining market share and profitability.
-
Regulatory Outlook: Patent expiry around [year] will be a major inflection point, prompting manufacturers to prepare biosimilar strategies.
-
Market Expansion: Broader indications and combination therapies could mediate price erosion effects by increasing volume sales.
FAQs
1. When does the patent for NDC 50242-0121 expire?
The patent is expected to expire around [year], after which biosimilar development may begin in earnest.
2. What are the main competitors for this drug?
Competitive landscape includes [list of biosimilars, branded alternatives, or off-label options], depending on the therapeutic area.
3. How have the prices of similar drugs evolved over the last five years?
Most biologics have maintained stable or modestly increasing prices, but significant reductions occur following patent expiration and biosimilar entry.
4. What strategies can manufacturers adopt to remain competitive?
Diversifying indications, improving delivery mechanisms, engaging in value-based contracts, and preparing biosimilar portfolios are key strategies.
5. How might healthcare policy changes impact pricing and access?
Policies aimed at drug price regulation, increased transparency, and value-based reimbursement could exert downward pressure on prices and influence formulary decisions.
References
- Industry reports on biologic and specialty drug markets.
- FDA database for approval and patent timelines.
- Market research studies from IQVIA, EvaluatePharma, and other authoritative sources.
- Healthcare policy analyses relevant to drug pricing and biosimilar regulation.
Disclaimer: This analysis utilizes hypothetical data aligned with typical market behaviors and should be supplemented with current, definitive proprietary data for precise decision-making.
More… ↓
